Download PDF
Semin Thromb Hemost 2016; 42(05): 526-532
DOI: 10.1055/s-0036-1571310
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement

Pier Mannuccio Mannucci
1   Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy
,
Maria Elisa Mancuso
1   Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy
,
Elena Santagostino
1   Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy
,
Massimo Franchini
2   Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
05 May 2016 (online)

   Permissions and Reprints

Abstract

In recent years, advances in the pharmacological treatment of hemophilias A and B have mainly focused on the development of long-acting factor (F)VIII and FIX products. Alternative approaches not based on the replacement of the missing factor have also been explored, with the aim of producing therapeutic agents with reduced immunogenicity and yet equally effective in patients with or without inhibitors. These new classes of hemostatic agents act mainly by bypassing the need of FVIII and FIX in tenase formation, quenching anticoagulant pathways, enhancing the activity of some coagulation factors or stabilizing the fibrin clot. Current knowledge on the status of development of these novel molecules is summarized in this narrative review. We also surmise that the main interests for these products not based on the replacement of FVIII or FIX in deficient patients pertain to the potential for bleeding prevention in inhibitor patients, an earlier and easier prophylaxis implementation thanks to subcutaneous administration and prolonged half-life, and a low immunogenicity with the potential for prevention of inhibitor development in high-risk patients.

Keywords

hemostatic agents - ACE910 - concizumab - antithrombin - FV variant - FX variant

Note

A new long-acting pegylated factor VIII produced by Baxalta is now licensed. A phase 1 study of ACE 910 in healthy subjects is now published in full.[59] The compound at doses up to 1 mg/kg was well tolerated and had no notable adverse hypercoagulable effect in 64 subjects.


 

  • References

  • 1 Mannucci PM, Tuddenham EGD. The hemophilias—from royal genes to gene therapy. N Engl J Med 2001; 344 (23) 1773-1779
    CrossrefPubMedGoogle Scholar
  • 2 Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379 (9824) 1447-1456
    CrossrefPubMedGoogle Scholar
  • 3 Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013; 27 (4) 179-184
    CrossrefPubMedGoogle Scholar
  • 4 White II GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J ; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85 (3) 560
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7: 24
    CrossrefPubMedGoogle Scholar
  • 6 Mannucci PM, Franchini M. Present and future challanges in the treatment of haemophilia: a clinician's perspective. Blood Transfus 2013; 11 (Suppl. 04) s77-s81
    PubMedGoogle Scholar
  • 7 Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus 2013; 11 (2) 178-182
    PubMedGoogle Scholar
  • 8 Manco-Johnson MJ, Abshire TC, Shapiro AD , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (6) 535-544
    CrossrefPubMedGoogle Scholar
  • 9 Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM ; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9 (4) 700-710
    CrossrefPubMedGoogle Scholar
  • 10 Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011; 72 (4) 553-562
    CrossrefPubMedGoogle Scholar
  • 11 Astermark J, Santagostino E, Keith Hoots W. Clinical issues in inhibitors. Haemophilia 2010; 16 (Suppl. 05) 54-60
    PubMedGoogle Scholar
  • 12 Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013; 39 (7) 772-778
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Gringeri A, Leissinger C, Cortesi PA , et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia 2013; 19 (5) 736-743
    CrossrefPubMedGoogle Scholar
  • 14 Konkle BA, Ebbesen LS, Erhardtsen E , et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5 (9) 1904-1913
    CrossrefPubMedGoogle Scholar
  • 15 Mannucci PM. Half-life extension technologies for haemostatic agents. Thromb Haemost 2015; 113 (1) 165-176
    PubMedGoogle Scholar
  • 16 Powell JS, Pasi KJ, Ragni MV , et al. BLONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369 (24) 2313-2323
    CrossrefPubMedGoogle Scholar
  • 17 Mahlangu J, Powell JS, Ragni MV , et al. ALONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123 (3) 317-325
    CrossrefPubMedGoogle Scholar
  • 18 Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost 2013; 11 (Suppl. 01) 84-98
    CrossrefPubMedGoogle Scholar
  • 19 Mannucci PM, Mancuso ME. Investigational drugs for coagulation disorders. Expert Opin Investig Drugs 2013; 22 (8) 945-953
    CrossrefPubMedGoogle Scholar
  • 20 Ragni MV. New and emerging agents for the treatment of hemophilia: focus on extended half-life recombinant clotting proteins. Drugs 2015; 75 (14) 1587-1600
    CrossrefPubMedGoogle Scholar
  • 21 Shetty S, Ghosh K. Novel therapeutic approaches for haemophilia. Haemophilia 2015; 21 (2) 152-161
    CrossrefPubMedGoogle Scholar
  • 22 Franchini M, Favaloro EJ, Lippi G. Newer hemostatic agents. Semin Thromb Hemost 2015; 41 (7) 802-808
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Mahlangu JN, Koh PL, Ng HJ, Lissitchkov T, Hardtke M, Schroeder J. The TRUST trial: anti-drug antibody formation in a patient with hemophilia with inhibitors after receiving the activated factor VII product Bay 86–6150 (Abstract). Blood 2015; 122 (21) 573
    PubMedGoogle Scholar
  • 24 Mahlangu JN, Weldingh KN, Lentz SR , et al; adept™2 Investigators; adept 2 Investigators. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J Thromb Haemost 2015; 13 (11) 1989-1998
    CrossrefPubMedGoogle Scholar
  • 25 Weimer T, Wormsbächer W, Kronthaler U, Lang W, Liebing U, Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99 (4) 659-667
    PubMedGoogle Scholar
  • 26 Zollner S, Schuermann D, Raquet E , et al. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). J Thromb Haemost 2014; 12 (2) 220-228
    CrossrefPubMedGoogle Scholar
  • 27 Golor G, Bensen-Kennedy D, Haffner S , et al. Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers. J Thromb Haemost 2013; 11 (11) 1977-1985
    CrossrefPubMedGoogle Scholar
  • 28 Rivard GE, Lillicrap D, Poon MC , et al. Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?. Haemophilia 2005; 11 (4) 335-339
    CrossrefPubMedGoogle Scholar
  • 29 Kitazawa T, Igawa T, Sampei Z , et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18 (10) 1570-1574
    CrossrefPubMedGoogle Scholar
  • 30 Muto A, Yoshihashi K, Takeda M , et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost 2014; 12: 206-213
    CrossrefPubMedGoogle Scholar
  • 31 Muto A, Yoshihashi K, Takeda M , et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014; 124 (20) 3165-3171
    CrossrefPubMedGoogle Scholar
  • 32 Shima M, Nanbusa H, Taki M , et al. Long-term safety and prophylactic efficacy of once-weekly subcutaneous administration of ACE910 in Japanese hemophilia A patients with and without FVIII inhibitors: interim results of the extension study of a phase 1 study (Abstract). J Thromb Haemost 2015; 13 (Suppl. 02) AS017
    PubMedGoogle Scholar
  • 33 Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 2014; 123 (19) 2934-2943
    CrossrefPubMedGoogle Scholar
  • 34 Dockal M, Hartmann R, Fries M , et al. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI). J Biol Chem 2014; 289 (3) 1732-1741
    CrossrefPubMedGoogle Scholar
  • 35 Hilden I, Lauritzen B, Sørensen BB , et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012; 119 (24) 5871-5878
    CrossrefPubMedGoogle Scholar
  • 36 Chowdary P, Lethagen S, Friedrich U , et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015; 13 (5) 743-754
    CrossrefPubMedGoogle Scholar
  • 37 Waters EK, Sigh J, Ezban M, Hilden I. Thrombin generation is increased in plasma from healthy males who have received concizumab, an antibody against tissue factor pathway inhibitor (ExplorerTM 2) (Abstract). J Thromb Haemost 2015; 13 (Suppl. 02) AS019
    PubMedGoogle Scholar
  • 38 Dockal M, Pachlinger R, Hartmann R , et al. Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-Antagonistic Aptamer BAX 499 (Abstract). Blood 2012; 120: 1104
    PubMedGoogle Scholar
  • 39 Bolliger D, Szlam F, Suzuki N, Matsushita T, Tanaka KA. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice. Thromb Haemost 2010; 103 (6) 1233-1238
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Ragni MV. Targeting antithrombin to treat hemophilia. N Engl J Med 2015; 373 (4) 389-391
    CrossrefPubMedGoogle Scholar
  • 41 Sehgal A, Barros S, Ivanciu L , et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21 (5) 492-497
    CrossrefPubMedGoogle Scholar
  • 42 Sorensen B, Mant T, Georgiev P , et al; on behalf of ALN-AT3 Investigators. A subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim phase 1 study results in patients with hemophilia A or B. J Thromb Haemost 2015; 13 (Suppl. 02) OR213 (abstract)
    PubMedGoogle Scholar
  • 43 Franchini M, Mannucci PM. Interactions between genotype and phenotype in bleeding and thrombosis. Haematologica 2008; 93 (5) 649-652
    CrossrefPubMedGoogle Scholar
  • 44 von Drygalski A, Bhat V, Gale AJ , et al. An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C. PLoS ONE 2014; 9 (8) e104304
    CrossrefPubMedGoogle Scholar
  • 45 von Drygalski A, Cramer TJ, Bhat V, Griffin JH, Gale AJ, Mosnier LO. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant. J Thromb Haemost 2014; 12 (3) 363-372
    CrossrefPubMedGoogle Scholar
  • 46 Bhat V, von Drygalski A, Gale AJ, Griffin JH, Mosnier LO. Synergistic effect in bleed reduction by superFVa and recombinant human FVIIa in vivo suggest a novel bypassing strategy for hemophilia patients with inhibitors. Blood 2014; 14 (Suppl): 692 (abstract)
    PubMedGoogle Scholar
  • 47 Wolf DL, Lin PH, Hollenbach S, Wong A, Phillips DR, Sinha U. Procoagulant activity of reversibly acylated human factor Xa. Blood 1995; 86 (11) 4153-4157
    PubMedGoogle Scholar
  • 48 Louvain-Quintard VB, Bianchini EP, Calmel-Tareau C, Tagzirt M, Le Bonniec BF. Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas. J Biol Chem 2005; 280 (50) 41352-41359
    CrossrefPubMedGoogle Scholar
  • 49 Bunce MW, Toso R, Camire RM. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood 2011; 117 (1) 290-298
    CrossrefPubMedGoogle Scholar
  • 50 Ivanciu L, Toso R, Margaritis P , et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat Biotechnol 2011; 29 (11) 1028-1033
    CrossrefPubMedGoogle Scholar
  • 51 Camire RM. Bioengineered factor Xa as a potential new strategy for hemophilia therapy. Expert Rev Hematol 2012; 5 (2) 121-123
    CrossrefPubMedGoogle Scholar
  • 52 Reema J, Patel-Hett S, Camire RM, Fruebis J, Pittman D. A zymogen-like factor Xa improves hemostasis in a murine bleeding model. Blood 2014; 14 (Suppl): 1476 (abstract)
    PubMedGoogle Scholar
  • 53 George LA, Thalji NK, Raffini LJ, Gimotty PA, Camire RM. Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L). J Thromb Haemost 2015; 13 (9) 1694-1698
    CrossrefPubMedGoogle Scholar
  • 54 Ivanciu L, Camire RM. Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity. Blood 2015; 126 (1) 94-102
    CrossrefPubMedGoogle Scholar
  • 55 Rea CJ, Foley JH, Sørensen B. Factor XIII in the treatment of hemophilia A. N Engl J Med 2012; 366 (3) 281-283
    CrossrefPubMedGoogle Scholar
  • 56 Rea CJ, Foley JH, Ingerslev J, Sørensen B. Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A. J Thromb Haemost 2011; 9 (3) 510-516
    CrossrefPubMedGoogle Scholar
  • 57 Powell JS. Lasting power of new clotting proteins. Hematology (Am Soc Hematol Educ Program) 2014; 2014 (1) 355-363
    CrossrefPubMedGoogle Scholar
  • 58 Peyvandi F, Mannucci PM, Garagiola I , et al. Source of factor VIII replacement (plasmatic or recombinant) and incidence of inhibitory alloantibodies in previously untreated patients with severe hemophilia A: the multicenter randomized SIPPET study (Abstract). Blood 2015; 126 (23) 5
    CrossrefPubMedGoogle Scholar
  • 59 Uchida N, Sambe T, Yoneyama K , et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016; 127: 1633-1641
    CrossrefPubMedGoogle Scholar